Johnson & Johnson Prescription Drug Litigation
Lewandowski v. Johnson and Johnson (D.N.J.): Cohen Milstein represents participants in Johnson & Johnson’s Group Health Benefits Plan in a putative ERISA class action, accusing the pharmaceutical giant of mismanaging its own health plans’ prescription drug program, costing employees millions of dollars in the form of higher payments for prescription drugs, higher out-of-pocket costs and co-pays, and, ultimately, lower wages in violation of ERISA.
Wells Fargo Health Plan Litigation
Navarro, et al. v. Wells Fargo & Co. (D. Minn.): Cohen Milstein is representing members of the Wells Fargo & Company Health Plan in a putative class action against Wells Fargo and senior executives for mismanaging Wells Fargo’s prescription-drug benefits program. Plaintiffs allege that such breaches of fiduciary duties and prohibited transactions have cost their ERISA plan and their employees millions of dollars in the form of higher payments for prescription drugs, higher premiums, higher out-of-pocket costs, and lower wages or limited wage growth.
JPMorgan Chase Prescription Drug Litigation
Stern v. JPMorgan Chase & Co. (S.D.N.Y.): Cohen Milstein represents participants in the JPMorgan Chase Health Care Insurance Program for Active Employees and its component Medical Plan in a proposed class action. Plaintiffs allege that JPMorgan systematically mismanaged its prescription-drug benefits program by agreeing to pay its pharmacy benefit manager, CVS Caremark, grossly inflated prescription drug prices, costing the health plan and its participants millions of dollars through higher payments for prescription drugs, higher premiums, higher out-of-pocket costs, higher deductibles, higher coinsurance, higher copays, and suppressed wages.